Literature DB >> 11117787

Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor.

A L Folpe1, C E Hill, D M Parham, P A O'Shea, S W Weiss.   

Abstract

The histologic and immunohistochemical differentiation of Ewing' s sarcoma/primitive neuroectodermal tumor (ES/PNET) from other small, blue, round cell tumors may be difficult. Despite initial promise, CD99 (MIC2) has not proven to be a specific marker. Approximately 90% of ES/PNET have a specific t(11; 22)(q24;q12) that results in fusion of the EWS and FLI-1 genes, and overexpression of FLI-1 protein. A recent study has shown immunohistochemical FLI-1 expression in five of seven of the ES/PNET cases tested. We evaluated FLI-1 expression in 132 well-characterized small, blue, round cell tumors. All tumors were immunostained for FLI-1 (1:40, Sc 356 polyclonal, Santa Cruz Biotechnology) using steam heat for epitope retrieval. Only nuclear staining was accepted as positive. Endothelial cells were strongly positive in all cases and served as an internal control. In many cases, a subset of lymphocytes also stained positive. No staining was seen in any other normal tissue. FLI-1 expression was seen in 29 of 41 (71%) ES/PNET, 7 of 8 (88%) lymphoblastic lymphomas, 0 of 8 poorly differentiated synovial sarcomas (PDSS), 0 of 32 rhabdomyosarcoma (RMS), 0 of 30 neuroblastomas, 0 of 8 esthesioneuroblastomas, 0 of 3 Wilms' tumors, 0 of 1 mesenchymal chondrosarcoma, and in 1 of 1 desmoplastic round cell tumor. This last case was known to have an EWS/WT-1 fusion. Although the EWS/FLI-1 fusion gene is specific for ES/PNET, FLI-1 protein expression is not. Significantly, the great majority of lymphoblastic lymphomas (also CD99-positive) are strongly FLI-1-positive. Immunohistochemical detection of FLI-1 may be valuable in confirming the diagnosis of ES/ PNET in cases in which molecular genetic evaluation is not feasible. FLI-1 protein expression is also helpful in distinguishing ES/PNET from other tumors that may be CD99-positive, such as PDSS and RMS. It is not surprising that some ES/ PNET are FLI-1-negative, because not all ES/PNET have the classic EWS/FLI-1, and some cases of ES/PNET may produce either low levels of protein or idiotypically different protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11117787     DOI: 10.1097/00000478-200012000-00010

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  58 in total

1.  Femoral mesenchymal chondrosarcoma with secondary aneurysmal bone cysts mimicking a small-cell osteosarcoma.

Authors:  Shalini A Amukotuwa; Peter F M Choong; Peter J Smith; Gerard J Powell; David Thomas; Stephen M Schlicht
Journal:  Skeletal Radiol       Date:  2005-11-18       Impact factor: 2.199

Review 2.  Role of ancillary techniques in profiling unclassified laryngeal malignancies.

Authors:  H Hellquist; J L Hunt; A Cardesa; A Skalova; P J Slootweg; A Rinaldo; A Ferlito
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

3.  Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.

Authors:  Antonio Llombart-Bosch; Isidro Machado; Samuel Navarro; Franco Bertoni; Patrizia Bacchini; Marco Alberghini; Apollon Karzeladze; Nikita Savelov; Semyon Petrov; Isabel Alvarado-Cabrero; Doina Mihaila; Philippe Terrier; Jose Antonio Lopez-Guerrero; Piero Picci
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

4.  The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.

Authors:  Ciğdem Vural; Omer Uluoğlu; Nalan Akyürek; Aynur Oğuz; Ceyda Karadeniz
Journal:  Pathol Oncol Res       Date:  2011-01-26       Impact factor: 3.201

5.  Epithelial marker expression does not rule out a diagnosis of Ewing's sarcoma family of tumours.

Authors:  Isidro Machado; Samuel Navarro; Jose A López-Guerrero; Marco Alberghini; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2011-09-02       Impact factor: 4.064

Review 6.  Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.

Authors:  Maria Tsokos; Rita D Alaggio; Louis P Dehner; Paul S Dickman
Journal:  Pediatr Dev Pathol       Date:  2012

7.  Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases.

Authors:  Paari Murugan; Priya Rao; Pheroze Tamboli; Bogdan Czerniak; Charles C Guo
Journal:  Pathol Oncol Res       Date:  2017-04-20       Impact factor: 3.201

8.  Clinical presentation and long-term outcome of primary spinal peripheral primitive neuroectodermal tumors.

Authors:  Xianzeng Tong; Xiaofeng Deng; Tao Yang; Chenlong Yang; Liang Wu; Jun Wu; Yuqiang Yao; Zhuang Fu; Shuo Wang; Yulun Xu
Journal:  J Neurooncol       Date:  2015-07-18       Impact factor: 4.130

9.  The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.

Authors:  Dita Gratzinger; Shuchun Zhao; Robert West; Robert V Rouse; Hannes Vogel; Elena Cubedo Gil; Ronald Levy; Izidore S Lossos; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2009-02       Impact factor: 2.493

10.  Clinicopathological and molecular spectrum of ewing sarcomas/PNETs, including validation of EWSR1 rearrangement by conventional and array FISH technique in certain cases.

Authors:  Bharat Rekhi; Ulrich Vogel; Ranjan Basak; Sangeeta B Desai; Nirmala A Jambhekar
Journal:  Pathol Oncol Res       Date:  2013-11-30       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.